Literature DB >> 23148804

Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how.

Vincenzo Bettoli1, Stefania Zauli, Anna Virgili.   

Abstract

INTRODUCTION: The chemoprevention refers to the use of various types of chemical agents for preventing carcinogenic progression. Systemic retinoids are the most studied chemopreventive agents due to their capacity to regulate cell proliferation and their demonstrated efficacy in several clinical studies.
OBJECTIVES: The aim of the authors was to give precise indications regarding the use of the systemic retinoid in the chemoprevention of non-melanoma skin cancer (NMSC).
METHODS: The authors reviewed the literature found through a search to MEDLINE (from 2001 to December 2011).
RESULTS: Both acitretin and isotretinoin are effective for the prevention of NMSC. Isotretinoin is preferred in xeroderma pigmentosum and nevoid basal cell carcinoma syndrome, whereas acitretin is more used in transplant recipients, psoriasis and severe sun damage.
CONCLUSION: Despite numerous studies of the literature concerning retinoids in chemoprevention of NMSC, precise details of the type of retinoid to use, dosage and the duration of this preventive treatment and how to manage side effects in the case of long-lasting treatment are still not uniform and comparable. Moreover, neither guidelines nor approval by Food and Drug Administration exist to regulate the use of retinoids in chemoprevention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23148804     DOI: 10.3109/09546634.2012.746634

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  7 in total

Review 1.  Review of Ocular Manifestations of Nevoid Basal Cell Carcinoma Syndrome: What an Ophthalmologist Needs to Know.

Authors:  Judy J Chen; Juliana Sartori; Vinay K Aakalu; Pete Setabutr
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Oct-Dec

Review 2.  New Enlightenment of Skin Cancer Chemoprevention through Phytochemicals: In Vitro and In Vivo Studies and the Underlying Mechanisms.

Authors:  Madhulika Singh; Shankar Suman; Yogeshwer Shukla
Journal:  Biomed Res Int       Date:  2014-03-17       Impact factor: 3.411

3.  Management Pearls on the Treatment of Actinic Keratoses and Field Cancerization.

Authors:  Jaime Piquero-Casals; Daniel Morgado-Carrasco; Yolanda Gilaberte; Rubén Del Rio; Antonio Macaya-Pascual; Corinne Granger; José Luis López-Estebaranz
Journal:  Dermatol Ther (Heidelb)       Date:  2020-07-17

4.  Squamous Cell Carcinoma as a Complication of Long-Term Hydroxyurea Treatment.

Authors:  Miłosz Lewandowski; Paweł Łukowicz; Jerzy Jankau; Jan Romantowski; Wioletta Barańska-Rybak
Journal:  Case Rep Dermatol       Date:  2021-11-30

5.  A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.

Authors:  Joo-Heung Lee; Jai-Il Youn; Tae-Yoon Kim; Jee-Ho Choi; Chul-Jong Park; Yong-Beom Choe; Hae-Jun Song; Nack-In Kim; Kwang-Joong Kim; Jeung-Hoon Lee; Hyun-Jeong Yoo
Journal:  BMC Dermatol       Date:  2016-07-25

Review 6.  Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas.

Authors:  Sean R Christensen
Journal:  F1000Res       Date:  2018-06-01

7.  Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2).

Authors:  J L W Lambert; S Segaert; P D Ghislain; T Hillary; A Nikkels; F Willaert; J Lambert; R Speeckaert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-08-13       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.